Press Releases and Blog
Blog
Fortune By: Tony LoSasso March 4, 2026 President Trump has repeatedly promised to bring down prescription drug prices. His Republican Congress says it shares that goal. But tucked inside the recently passed 2026 Consolidated Appropriations Act is a restructuring of the drug market that makes lower prices less likely, not more. How does […]
PharmaVoice By Alivia Kaylor February 27, 2026 For over a decade, pharmacy benefit managers have been in the hot seat, absorbing the bulk of Washington’s bipartisan scrutiny over rising prescription drug costs. Now, the pricing pendulum is swinging back in pharma’s direction. Sweeping reforms in the Consolidated Appropriations Act of 2026, signed into law […]
The enactment of PBM reforms last month was a victory for the big drugmaker’s diversion campaign. But now that PBM reform – and the distractions – is done it’s important to reaffirm the immense value PBMs provide patients, employers, and the entire health care system in order to prevent further unintended consequences for employers and patients. An analysis by George S. […]
At a House Energy and Commerce subcommittee hearing last week, the full pharmaceutical drug supply chain testified, including a group that professes to represent employer interests. In one of the more fascinating exchanges, a member of the subcommittee sought to better understand how rebates become part of employer contracts with their pharmacy benefit manager (PBM). […]
Congress recently enacted government mandates on employers and pharmacy benefit managers (PBMs) – the ones who counter the pricing power of Big Pharma and deliver savings for American patients and employers. This intervention, dictating contract terms for employers and PBMs, was the result of a years-long campaign by Big Pharma to distract attention and keep […]
Earlier this month, the president signed into law significant new mandates on employers and pharmacy benefit managers – full PBM transparency, full rebate pass-through, Medicare delinking. These were big wins for the big drugmakers who’ve long invested heavily in diverting attention away from their role in the ridiculous prices charged for prescription drugs in America. […]
Press Releases
PBMs are transparent and reduce drug costs in New Jersey The Pharmaceutical Care Management Association (PCMA) issued the following statement on New Jersey Governor Mikie Sherrill’s budget address: “The governor’s remarks today about pharmacy benefit managers (PBMs) are simply untrue and misleading to New Jersey patients, and it is imperative to correct the record. The […]
Now, Congress Should Make Biosimilars Interchangeable (Washington, D.C.) – The Trump Administration is taking action to increase access to biosimilars. Congress can take the administration’s lead and entirely eliminate the interchangeability designation for biosimilars. In response to the new draft guidance, issued yesterday by the Food and Drug Administration, Pharmaceutical Care Management Association President and CEO, David […]
(Washington, D.C) – Several state legislatures and some federal lawmakers have considered a dangerous policy, known as “Forced Pharmacy Closure,” that bars integration between pharmacy benefit managers and pharmacies. If implemented, the result – shutting down hundreds or thousands of pharmacies – would inflict grave economic consequences and put the health of patients at risk, according […]
In his State of the Union address Tuesday night, President Donald Trump spoke about the need to lower drug prices in America, a primary focus of pharmacy benefit manager (PBM) companies. In response, Pharmaceutical Care Management Association President and CEO David Marin released the following statement: “Tonight, President Trump spoke to our shared goal of making health […]
Employers report high satisfaction with drug savings PBMs get and the transparency they provide (Washington, D.C.) — A new survey released today shows American employers are highly satisfied with their pharmacy benefit manager (PBM) relationship. The survey results found PBMs are exceeding employers’ expectations in key performance areas, including the amount of savings they get on […]
(Washington, D.C.) — Today, the Pharmaceutical Care Management Association (PCMA) released new data that provides a snapshot of the health of independent pharmacies in the United States. The findings reveal that the overall number of independent pharmacies in the U.S. grew from 2025 to 2026, according to new data from the National Council for Prescription Drug […]
Federal probe into PBM practices stalls after split vote
issue to a vote again as soon as possible. The Pharmaceutical Care Management Association, a national group that represents PBMs, pointed
FTC declines to investigate pharmacy benefit managers
Pharmacy benefit managers argue that they have been fighting to reduce net prices for consumers and that they have saved the public billions of dollars on their annual drug costs.
Drug Price Reporting Rules Foiled by Loopholes in Supply Chain
The PBM industry points to a number of data and timing elements that it believes exceeds the statutory authority. The Pharmaceutical Care Management Association, which represents PBMs, said in its comment letter that the rule goes beyond the agencies’ statutory authority and asked that “amounts retained by PBMs” be excluded.
Pharmacy Liaison Probe Must Be More ‘Rigorous’ to Get FTC Vote
But the Pharmaceutical Care Management Association, the leading PBM trade group, said in a statement after the vote that “drug manufacturer price setting is the root cause of high drug costs, putting a strain on patients and forcing them to make difficult decisions about their drugs.”
Pharmacy Agent Study Would Show Role in Drug Price ‘Dysfunction’
The Pharmaceutical Care Management Association, the leading PBM trade group, said in a statement that it’s “confident the FTC will ultimately conclude that drug manufacturer price setting is the root cause of high drug costs, putting a strain on patients and forcing them to make difficult decisions about their drugs.”
Despite Narrow Confirmation, Associations Praise New FDA Commissioner Califf
Meanwhile, the Pharmaceutical Care Management Association said in a statement emailed to FormularyWatch® that it looks forward to working with Califf and the FDA on ways to reduce prescription drug costs for patients. “Increased competition in the prescription drug marketplace is important to achieving the shared goal of increasing affordability and access to prescription drugs,” PCMA said.
Skyrocketing drug prices: A deep dive into the partisan divide in Congress over how to fix it
In a statement, PCMA said: “Any report that focuses only on pharmacy benefit managers (PBMs) seems to purposefully take a narrow view and is therefore going to miss the mark. PBMs are the only entity in the drug and payment supply chain that actually reduces prescription drug costs for patients. Instead, policymakers should focus on increasing affordability for patients through more competition, market forces, and a focus on getting value for scarce health care dollars.”
FTC will vote on whether to examine how PBM practices may hurt pharmacies and drug prices
“We welcome any opportunity to further demonstrate how pharmacy benefit managers reduce drug costs through competition, enabling better patient access to the best possible care. Drug prices continue to go up, putting a strain on patients, and forcing them to make difficult decisions about taking their drugs,” the Pharmaceutical Care Management Association, said in a statement.
COVID-19 antiviral dispensing fees are too low, pharmacies say
The Pharmaceutical Care Management Association, a trade group representing PBMs, said they are “making voluntary payments to pharmacies in order to maintain appropriate access to the medications for patients” in an emailed statement to Bloomberg Law.
Lack Of Reimbursement Forces Colorado Pharmacy To Not Offer Antiviral COVID Pill Paxlovid
JC Scott, the President & CEO of the Pharmaceutical Care Management Association (PCMA), which represents pharmacy benefit managers, said PBMs are “voluntarily paying dispensing fees for these drugs, which are not technically covered by Medicare and other insurance.”
